Recruiting Clinical Trials
Institute | Protocol No. | Trial name | Cancer Site | Experimental Treatment Agent | Key Eligibility Criteria | Principal Investigator | Study Coordinator Contact |
---|---|---|---|---|---|---|---|
HKU |
ARC-10 |
A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB 154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Locally Advanced / Metastatic NSCLC |
Zimberelimab (AB 122) |
1. Histologically confirmed, treatment naïve, locally advanced or metastatic (Stage IIIB - IV), squamous or non-squamous NSCLC with documented high PD-L1 Expression |
Dr Victor LEE |
Vera WONG |
HKU |
Cullinan-Pearl |
A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations |
NSCLC |
CLN-081 |
1. Documented EGFR exon 20 insertion mutation demonstrated by a test routinely used by each institution and performed in a CLIA-certified or equivalent laboratory. |
Dr Victor LEE |
Vera WONG 2255 5034 |
HKU |
DS8201-A-U305 |
A Phase 3, Multicenter, Randomized, Open-Label, |
HER2+ BC |
Trastuzumab deruxtecan (T-DXd) |
1. Pathologically documented HER2-positive breast cancer (BC) |
Dr Wendy CHAN |
Bryan Kwan |
HKU |
DS8201-A-U306 |
A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04) |
Gastric/GEJ (2nd line) |
Trastuzumab deruxtecan vs |
1. Progression on or after first-line therapy with a trastuzumab or approved trastuzumab biosimilar-containing regimen |
Dr LAM Ka On |
Michael WONG 2255 4216 |
HKU |
Mermaid-2 |
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy |
NSCLC |
Durvalumab |
Stage II-III NSCLC |
Dr Victor LEE |
Vera WONG 2255 5034 |
HKU |
A multi-centre phase II randomized-controlled study on addition of durvalumab (MEDI4736) to induction chemotherapy and concurrent chemoradiation and followed by maintenance durvalumab for locoregionally advanced nasopharyngeal carcinoma |
NPC |
Durvalumab |
1. Previously untreated stage III-IVA nasopharyngeal carcinoma |
Dr Victor LEE |
Mike LAW 2255 5124 |
|
HKU |
A multi-centre single-arm phase II study on durvalumab (MEDI 4736) with stereotactic body radiation therapy (SBRT) in patients with inoperable/unresectable hepatocellular carcinoma |
inoperable / unresectable hepatocellular carcinoma |
Durvalumab with SBRT |
1. Histologically or radiologically confirmed HCC |
Dr Victor LEE |
Mike LAW 2255 5124 |
|
HKU |
MK-3475-975 |
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) |
Esophageal Carcinoma |
Pembrolizumab + Chemoradiotherapy |
1. Receiving concurrent definitive chemoradiotherapy |
Prof Dora KWONG |
Bryan Yun |
HKU |
MK7902-014 |
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma |
Metastatic Esophageal Carcinoma |
Pembrolizumab + Lenvatinib + Chemotherapy vs Pembrolizumab + Chemotherapy |
1. Metastatic squamous cell carcinoma of the esophagus |
Professor Dora KWONG |
Bryan Yun |
HKU |
MK-7902-015 |
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) |
advanced/metastatic gastroesophageal cancer |
Lenvatinib + CAPOX/mFOLFOX6 vs CAPOX/mFOLFOX6 |
1. Previously untreated, locally advanced unresectable / metastatic gastroesophageal adenocarcinoma |
Dr Chan Wing Lok Wendy |
Michael WONG 2255 4216 |
hku |
OBI-822-011 |
|
TNBC |
Adagloxad Simolenin + OBI-821 |
|
Dr Wendy CHAN |
Bryan Kwan |
HKU |
TAS-102 |
Phase II Trial of TAS-102 in Patients with Advanced, Refractory Pancreatic Adenocarcinoma |
Pancreatic Cancer |
TAS-102 |
1. Histological or cytological confirmed advanced or metastatic pancreatic cancer |
Dr CHIANG Chi Leung |
Isabel CHAN/ Nate CHAN |
HKU |
TAC-GReD |
Combination Talazoparib - carboplatin for recurrent high-grade glioma with DNA damage repair deficiency (DDRd) “TAC-GReD” trial |
high-grade glioma |
Talazoparib + carboplatin |
Recurrent high grade glioma with DDRd, defined by genomic aberrations associated including IDH mutation, PTEN mutation and “BRCAness” signature (ATM, ATR, BAP1, BRCA1, BRCA2, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, PALB2, NGS1, WRN, RAD50, RAD51B, RAD51C, RAD51D, MRE11A, BLM, BRIP1) |
Dr. Aya El Helali |
Angela IU 2255 5124 |